Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$118.35 USD
-2.11 (-1.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $118.42 +0.07 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NBIX 118.35 -2.11(-1.75%)
Will NBIX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NBIX
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
Other News for NBIX
Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
Voyager advances Neurocrine collaboration, selects third gene therapy candidate
Neurocrine Biosciences Provides Update on ERUDITE? Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), McKesson (MCK) and Neurocrine (NBIX)